ELI LILLY AND COMPANY Number of Reportable Segments
ELI LILLY AND COMPANY (LLY) reported Number of Reportable Segments of 1 segment for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Segment Reporting
us-gaap:NumberOfReportableSegments · last filed 2026-08-05
- ELI LILLY AND COMPANY number of reportable segments for the quarter ending 2026-03-31 was 1.00 segment, a 0.00% change year-over-year.
- ELI LILLY AND COMPANY number of reportable segments for the quarter ending 2025-03-31 was 1.00 segment.
- ELI LILLY AND COMPANY number of reportable segments for fiscal 2025 was 1.00 segment, a 0.00% change from fiscal 2024.
- ELI LILLY AND COMPANY number of reportable segments for fiscal 2024 was 1.00 segment.
| Period end | Number of Reportable Segments 3 month | Number of Reportable Segments 6 month | Number of Reportable Segments 9 month | Number of Reportable Segments 12 month |
|---|---|---|---|---|
| 2026-06-30 | 1.00 segment 10-Q · filed 2026-08-05 | |||
| 2026-03-31 | 1.00 segment 10-Q · filed 2026-04-30 | |||
| 2025-12-31 | 1.00 segment 10-K · filed 2026-02-12 | |||
| 2025-09-30 | 1.00 segment 10-Q · filed 2025-10-30 | |||
| 2025-06-30 | 1.00 segment 10-Q · filed 2025-08-07 | |||
| 2025-03-31 | 1.00 segment 10-Q · filed 2025-05-01 | |||
| 2024-12-31 | 1.00 segment 10-K · filed 2025-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |